<DOC>
	<DOCNO>NCT01358071</DOCNO>
	<brief_summary>The primary objective randomize phase II trial compare progression-free survival ( PFS ) patient randomize NGR-hTNF plus anthracycline versus patient randomized anthracycline alone</brief_summary>
	<brief_title>Phase II Study NGR-hTNF Combination With Doxorubicin Platinum-resistant Ovarian Cancer</brief_title>
	<detailed_description>Considering safety/toxicity profile NGR-hTNF characterize mild-to-moderate constitutional symptom , reversibility adverse event generally occur infusion time ; absence overlap toxicity chemotherapeutic agent ; safety preliminary antitumor activity observe previous trial doxorubicin ; objective response rate ( RR ) register phase II trial previously treat ovarian cancer patient seem justified evaluate randomize phase II trial efficacy NGR-hTNF doxorubicin-based option advance ovarian cancer patient progress recurrent standard platinum/taxane-based chemotherapy .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Age â‰¥ 18 year Histologicallyproven ovarian cancer , fallopian tube primary peritoneal cancer advance metastatic stage Patients previously treat maximum two platinumbased regimen plus paclitaxel document progressive disease treatment ( refractory patient population ) within 6 month last chemotherapy cycle ( resistant patient population ) Good clinical Conditions Normal cardiac function Adequate baseline bone marrow , hepatic renal function At least one ( previously irradiate ) target lesion nonmeasurable disease , accord RECIST criterion Patients may prior therapy provide follow condition meet : Surgery radiation therapy : washout period 14 day Systemic antitumor therapy : washout period 21 day Patients may receive investigational agent study More two previous chemotherapy line previous treatment anthracycline Patients myocardial infarction within last six month , unstable angina , New York Heart Association ( NYHA ) grade II great congestive heart failure , serious cardiac arrhythmia require medication Prolonged QTc interval ( congenital acquire ) &gt; 450 ms History evidence upon physical examination CNS disease unless adequately treated Patients active uncontrolled systemic disease/infections serious illness medical condition , incompatible protocol Known hypersensitivity/allergic reaction human albumin preparation excipients Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol Pregnancy lactation .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>NGR-hTNF</keyword>
	<keyword>Pegylated liposomal doxorubicin</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Platinum-resistant</keyword>
	<keyword>Progression recurrence Ovarian Cancer</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Advanced metastatic</keyword>
</DOC>